Read by QxMD icon Read

Botox and incontinence

Pawel Miotla, Rufus Cartwright, Katarzyna Skorupska, Michal Bogusiewicz, Ewa Markut-Miotla, Konrad Futyma, Tomasz Rechberger
AIMS: Urgency urinary incontinence (UUI), and the symptoms of overactive bladder (OAB) have a negative impact on female sexual function. The aim of this study was to investigate the effect of intravesical onabotulinumtoxinA (Botox) injection on sexual function in women with OAB, using the multi domain Female Sexual Function Index (FSFI) questionnaire. METHODS: Sixty-eight sexually active women with idiopathic OAB with at least one episode of UUI and ≥8 micturitions per 24 h were recruited...
October 4, 2016: Neurourology and Urodynamics
Laura Weglinski, Rebecca Haddad, Benoit Peyronnet, Xavier Game, Calin Ciofu, Gerard Amarenco
OBJECTIVE: Intradetrusorial injection of botulinum toxin A (IDBT) is a validated treatment for neurogenic and non-neurogenic refractory overactive bladder. In the elderly, muscarinic antagonists have many side effects, in particular in cognition. An alternative treatment is, for that reason, interesting in this frail population with multiple medication use. The question of efficacy is remaining. Indeed, bladder dysfunction is most of the time a multifactorial issue in the elderly. The objective of this study was to evaluate prospectively the efficacy and safety of IDBT in this population...
September 2016: Annals of Physical and Rehabilitation Medicine
Anthony G Visco, Halina Zyczynski, Linda Brubaker, Ingrid Nygaard, Xiao Xu, Emily S Lukacz, Marie Fidela Paraiso, Jerod Greer, David D Rahn, Susan F Meikle, Amanda A Honeycutt
OBJECTIVES: This study aimed to compare the cost-effectiveness of Botox and anticholinergic (AC) medications for the management of urgency urinary incontinence (UUI). METHODS: Cost and effectiveness data were analyzed from participants in the Anticholinergic versus Botox Comparison randomized trial of daily AC medication versus 100 U of intradetrusor Botox injection. Societal costs included the following: treatment costs, patient costs, and medical and nonmedical utilization during the 6-month trial...
September 2016: Female Pelvic Medicine & Reconstructive Surgery
Adam Bobkiewicz, Wojciech Francuzik, Lukasz Krokowicz, Adam Studniarek, Witold Ledwosiński, Jacek Paszkowski, Michal Drews, Tomasz Banasiewicz
BACKGROUND: Chronic anal fissure (CAF) is a linear split of the anoderm. The minimally invasive management of CAF such as botulinum toxin (BT) injection is recommended. However, the exact efficient dose of BT, number of injections per session and the injection sites are still debatable. The aim of this analysis was to assess the dose-dependent efficiency of botulinum toxin injection for CAF. METHODS: PubMed and Web of Science databases were searched for terms: "anal fissure" AND "botulinum toxin...
December 2016: World Journal of Surgery
(no author information available yet)
In two clinical trials, botulinum toxin injected during cystoscopy transiently prevented urinary incontinence in 1 in 5 patients but sometimes provoked urine retention and urinary tract infections.
March 2016: Prescrire International
Benoit Peyronnet, Evelyne Castel-Lacanal, Mathieu Roumiguie, Lucie Even, Philippe Marque, Michel Soulié, Pascal Rischmann, Xavier Game
AIMS: To compare the outcomes of the first intradetrusor injections of abobotulinum toxin 750 U and onabotulinum toxin 200 and 300 U in patients with neurogenic detrusor overactivity (NDO). METHODS: A retrospective case-control study was conducted including 211 NDO patients treated in three consecutives eras with onabotulinum toxin 300 U (2004-2006; 80 patients), abobotulinum toxin 750 U (2007-2011; 78 patients) or onabotulinum toxin 200 U (2011-2014; 53 patients)...
March 31, 2016: Neurourology and Urodynamics
Pawel Miotla, Rufus Cartwright, Konrad Futyma, Michal Bogusiewicz, Katarzyna Skorupska, Izabela Winkler, Tomasz Rechberger
AIMS: Despite the efficacy of intravesical onabotulinumtoxinA (Botox) therapy for urgency, urgency incontinence, and daytime frequency, its value in treatment of nocturia remains unclear. The aim of the prospective observational study was to assess the effect of onabotulinumtoxinA on night-time symptoms in women with overactive bladder (OAB), including nocturia, night-time urgency incontinence, and nocturnal voided volume as end-points. METHODS: Women with idiopathic OAB (with at least one episode of urgency urinary incontinence (UUI) per day, ≥8 micturitions per 24 hr, and ≥2 nocturia episodes per night) were enrolled...
February 24, 2016: Neurourology and Urodynamics
Filip Weckx, Manuela Tutolo, Dirk De Ridder, Frank Van der Aa
Neurogenic detrusor overactivity (NDO) can result in lower and upper urinary tract complications and eventually even in end-stage kidney failure. Since the driving force of this clinical cascade is high bladder pressure, controlling intravesical pressure in NDO patients improves both quality of life and life-expectancy in these patients. Botulinum toxin A (BTX-A) has proven its efficacy in reducing intravesical pressure and in reducing incontinence episodes. BTX-A also improves quality of life in patients with NDO...
February 2016: Translational Andrology and Urology
Christopher P Smith, Michael B Chancellor
Alteration in neural control from suprapontine areas to the nerves innervating the bladder can lead to bladder dysfunction and the development of a neurogenic bladder (NGB). Patients with NGB often suffer from urinary incontinence, which can lead to adverse events such as urinary tract infections and decubiti, in addition to creating a large care burden for family members or healthcare providers and significantly impairing patient quality of life. The common failure of anticholinergic medications has spurned the development of second-line treatments, including the use of botulinum toxin...
February 2016: Seminars in Neurology
Sheng-Mou Hsiao, Ho-Hsiung Lin, Hann-Chorng Kuo
OBJECTIVES: To analyze the predictors of therapeutic efficacy after intravesical botulinum toxin A injection for overactive bladder syndrome (OAB) refractory to antimuscarinic therapy. METHODS: All consecutively OAB patients, who visited the urologic outpatient clinics of a medical center and refractory to antimuscarinic treatment, were prospectively enrolled. All enrolled patients received intravesical injection of 100 U onabotulinumtoxinA (Botox). The Global Response Assessment (GRA) score ≥ 2 at 3 months after Botox injection was defined as a successful treatment, otherwise failed...
2016: PloS One
Gwen M Grimsby, Micah A Jacobs, Vani Menon, Bruce J Schlomer, Patricio C Gargollo
PURPOSE: Complex urological reconstruction may be facilitated by the improved magnification and dexterity provided by a robotic approach. Minimally invasive surgery also has the potential advantages of decreased length of stay and improved convalescence. We reviewed perioperative and short-term outcomes between robot-assisted and open bladder neck sling/repair with catheterizable channel in patients with neurogenic bladder. MATERIALS AND METHODS: We performed an institutional review board approved retrospective chart review of all patients who underwent open or robotic bladder neck reconstruction without augmentation cystoplasty for refractory urinary incontinence between 2010 and 2014...
April 2016: Journal of Urology
Ruchira Singh, Sherif A El Nashar, Emanuel C Trabuco, Christopher J Klingele, John B Gebhart, John A Occhino
OBJECTIVES: The aim of the study was to compare the short-term outcomes of sacral nerve stimulation (SNS) and intradetrusor injection of OnabotulinumtoxinA (Botox) for overactive bladder (OAB) symptoms refractory to behavioral modifications and pharmacologic therapy. METHODS: This is a retrospective cohort study evaluating the outcomes of SNS and Botox procedures that were performed for refractory OAB symptoms at a tertiary care referral center. The primary outcome was "failure" of treatment that was defined as less than 50% improvement from the baseline symptoms at 6 months...
November 2015: Female Pelvic Medicine & Reconstructive Surgery
Jameel Nazir, Khaled Maman, Mohamed-Elmoctar Neine, Benjamin Briquet, Isaac A O Odeyemi, Zalmai Hakimi, Andy Garnham, Samuel Aballéa
BACKGROUND: Mirabegron, a first-in-class selective oral β3-adrenoceptor agonist, has similar efficacy to most antimuscarinic agents and a lower incidence of dry mouth in patients with overactive bladder (OAB). OBJECTIVES: To evaluate the cost-effectiveness of mirabegron 50 mg compared with oral antimuscarinic agents in adults with OAB from a UK National Health Service perspective. METHODS: A Markov model including health states for symptom severity, treatment status, and adverse events was developed...
September 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Pawel Miotla, Konrad Futyma, Rufus Cartwright, Michal Bogusiewicz, Katarzyna Skorupska, Ewa Markut-Miotla, Tomasz Rechberger
INTRODUCTION AND HYPOTHESIS: Intravesical onabotulinumtoxinA (Botox®) is effective for idiopathic overactive bladder (OAB) symptoms. Our primary objective was to compare the efficacy of onabotulinumtoxinA for women with de novo OAB after midurethral sling (MUS) surgery and women with idiopathic OAB. METHODS: Women enrolled in this prospective study had idiopathic (n = 53) or de novo (n = 49) OAB symptoms after MUS, with at least one episode of urgency urine incontinence per day...
March 2016: International Urogynecology Journal
B Peyronnet, S Sanson, G Amarenco, E Castel-Lacanal, E Chartier-Kastler, K Charvier, M Damphousse, P Denys, M de Seze, G Egon, A Even, V Forin, G Karsenty, J Kerdraon, L le Normand, C-M Loche, A Manunta, P Mouracade, V Phe, J-G Previnaire, A Ruffion, C Saussine, B Schurch, X Game
OBJECTIVE: There is currently no guideline regarding the management of neurogenic detrusor overactivity (NDO) refractory to intra-detrusor botulinum toxin injections. The primary objective of the present study was to find a consensus definition of failure of botulinum toxin intra-detrusor injections for NDO. The secondary objective was to report current trends in the managment of NDO refractory to botulinum toxin. METHODS: A survey was created, based on data drawn from current literature, and sent via e-mail to all the experts form the Group for research in neurourology in french language (GENULF) and from the comittee of neurourology of the French urological association (AFU)...
December 2015: Progrès en Urologie
Sara Bibi, Massarat Zutshi, Brooke Gurland, Tracy Hull
PURPOSE: The aim of this study was to evaluate the efficacy of Botulinum toxin-A (Botox) in relieving anal pain associated with anal fissure (AF) and Levator ani syndrome (LS). METHODS: All patients with medically refractory AF or LS from 2005 to 2012 and treated with Botox injections were included. RESULTS: One hundred and three patients [66 patients (53 female) with AF and 37 patients (26 female) with LS] were evaluated. The minimum/maximum dose of Botox was 20/100 units for AF and 50/200 units for LS...
January 2016: Postgraduate Medicine
Waleed Al Taweel, Khalil Mohammed Alzyoud
AIM: The aim was to report the effectiveness and safety OnabotulinumtoxinA (Botox, Allergan, Inc., Irvine, CA, USA) intradetrusor injections in spinal cord-injured (SCI) patients with refractory neurogenic detrusor overactivity. And to assess the result based on SCI level. MATERIALS AND METHODS: We reviewed the chart of 103 patients with neurogenic bladder secondary to SCI at the rehab center who received OnabotulinumtoxinA in our Neurourology Department for treatment of lower urinary tract symptoms between January 2007 and December 2013...
July 2015: Urology Annals
Calin Chibelean, Ioan Alin Nechifor-Boila
INTRODUCTION: Overactive bladder (OAB) syndrome is a special condition characterized by urgency, with or without urinary urge incontinence (UUI), associated to frequency and nocturia, with important consequences on patients' quality of life (QoL). Administered as intradetrusor injections, botulinum neurotoxin type A (BoNT/A) is a new, promising, minimally invasive treatment option for OAB patients, non-compliant to conventional antimuscarinics. The aim of our study was to perform a systematic review of the literature concerning the efficiency and safety of different BoNT/A products in the treatment of OAB...
April 2015: Canadian Journal of Urology
Rizwan Hamid, Clara Loveman, Jim Millen, Denise Globe, Catherine Corbell, Danielle Colayco, Sanja Stanisic, Dmitry Gultyaev
OBJECTIVES: To evaluate the cost effectiveness of onabotulinumtoxinA (BOTOX(®), 200 units [200 U]) for the management of urinary incontinence (UI) in adults with neurogenic detrusor overactivity (NDO) due to subcervical spinal cord injury or multiple sclerosis that is not adequately managed with anticholinergic drugs (ACHDs). PERSPECTIVE: UK National Health Service (NHS) perspective. METHODS: A Markov state-transition model was developed, which compared onabotulinumtoxinA + best supportive care (BSC) with BSC alone (comprising behavioural therapy and pads, alone or in combination with clean intermittent catheterization and possibly with ACHDs)...
April 2015: PharmacoEconomics
Atsushi Sengoku, Kikuo Okamura, Yasusuke Kimoto, Takatoshi Ogawa, Takashige Namima, Tomonori Yamanishi, Teruhiko Yokoyama, Hironobu Akino, Yoshiko Maeda
OBJECTIVES: To examine the efficacy and safety of onabotulinumtoxinA (Botox) injection into the bladder wall for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury in Japanese patients. METHODS: We enrolled Japanese spinal cord injury patients with cystometrically confirmed neurogenic detrusor overactivity who experienced urinary incontinence at least once a week either because they were refractory to anticholinergics or had to discontinue treatment because of adverse events...
March 2015: International Journal of Urology: Official Journal of the Japanese Urological Association
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"